Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume – Still a Buy?

Shares of Oculis Holding AG (NASDAQ:OCS) saw strong trading volume on Friday . 63,615 shares traded hands during mid-day trading, an increase of 48% from the previous session’s volume of 43,047 shares.The stock last traded at $18.10 and had previously closed at $17.40.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on OCS. Robert W. Baird upped their price target on shares of Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a report on Thursday, March 13th. Chardan Capital restated a “buy” rating and set a $28.00 target price on shares of Oculis in a research note on Thursday, April 17th. Finally, HC Wainwright lifted their price target on Oculis from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, April 17th.

Oculis Stock Performance

The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $823.90 million, a price-to-earnings ratio of -9.78 and a beta of 0.19. The stock’s 50-day moving average is $18.13 and its 200-day moving average is $18.26.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.28). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. On average, analysts predict that Oculis Holding AG will post -2.09 EPS for the current fiscal year.

Institutional Trading of Oculis

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its position in Oculis by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock worth $284,000 after buying an additional 1,800 shares during the period. Bellevue Group AG acquired a new position in shares of Oculis during the fourth quarter worth $170,000. Bank of America Corp DE grew its stake in shares of Oculis by 58.2% in the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock worth $493,000 after purchasing an additional 10,667 shares during the last quarter. XTX Topco Ltd acquired a new stake in Oculis in the fourth quarter valued at $225,000. Finally, Citadel Advisors LLC acquired a new position in Oculis during the 4th quarter worth about $389,000. 22.30% of the stock is currently owned by institutional investors.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.